Tigecycline in the management of post-neurosurgical spondylodiscitis: a review of eight cases

Basit Öğe Kaydı
dc.contributor.authorSipahi, Oguz Resat
dc.contributor.authorKahraman, Hasip
dc.contributor.authorMermer, Sinan
dc.contributor.authorPullukcu, Husnu
dc.contributor.authorTasbakan, Meltem
dc.contributor.authorArda, Bilgin
dc.contributor.authorYamazhan, Tansu
dc.contributor.authorYurtseven, Taskin
dc.contributor.authorAydemir, Sohret
dc.contributor.authorUlusoy, Sercan
dc.date.accessioned2019-10-27T22:14:45Z
dc.date.available2019-10-27T22:14:45Z
dc.date.issued2014
dc.departmentEge Üniversitesien_US
dc.description.abstractBackground: Tigecycline is a relatively new glycylcycline antimicrobial, active in vitro against a variety of Gram-positive and Gram-negative organisms. In this study we evaluated the outcomes of spondylodiscitis cases treated with tigecycline-including therapies retrospectively. Methods: All adult (age > 18 years) cases with a diagnosis of spondylodiscitis, who were treated with a tigecycline-including therapy between 2007 and 2011, were included in the study. The primary efficacy outcome was clinical success with tigecycline at the end of induction, while the secondary efficacy outcome was maintenance of success through 3 months following completion of induction. Results: A total of eight spondylodiscitis cases fulfilled the study inclusion criteria. All cases had back pain, restricted mobility, magnetic resonance findings associated with spondylodiscitis, and microbiology or pathological findings related to spondylodiscitis. All had post-neurosurgical spondylodiscitis. In five cases, tigecycline was started in accordance with the antibacterial susceptibility results from intervertebral tissue biopsy cultures, whereas in three it was started empirically. All cases had received several different antibacterials with failure before receiving tigecycline. The mean duration of tigecycline treatment was 37 +/- 21 days. One case was lost to follow-up after 2 days of tigecycline. Primary and secondary success was achieved in the remaining seven cases. Conclusions: These limited data suggest that tigecycline may have a role in the treatment of refractory spondylodiscitis cases. (C) 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.en_US
dc.identifier.doi10.1016/j.ijid.2014.01.027en_US
dc.identifier.endpage19en_US
dc.identifier.issn1201-9712
dc.identifier.issn1878-3511
dc.identifier.pmid24657273en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage16en_US
dc.identifier.urihttps://doi.org/10.1016/j.ijid.2014.01.027
dc.identifier.urihttps://hdl.handle.net/11454/50063
dc.identifier.volume23en_US
dc.identifier.wosWOS:000336383000005en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevier Sci Ltden_US
dc.relation.ispartofInternational Journal of Infectious Diseasesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectSpondylitisen_US
dc.subjectNosocomialen_US
dc.subjectHospital-acquireden_US
dc.subjectHealthcare-associated infectionen_US
dc.subjectAcinetobacter baumanniien_US
dc.subjectCarbapenem-resistanten_US
dc.titleTigecycline in the management of post-neurosurgical spondylodiscitis: a review of eight casesen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu